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Abstract
Introduction: The incidence of deep venous thrombosis (DVT) related to a central venous catheter varies
considerably in ICUs depending on the population included. The aim of this study was to determine subclavian
central venous catheter (SCVC)-related DVT risk factors in severely traumatized patients with regard to two kinds of
polyurethane catheters.
Methods: Critically ill trauma patients needing a SCVC for their usual care were prospectively included in an
observational study. Depending on the month of inclusion, patients received one of the two available products in
the emergency unit: either an aromatic polyurethane SCVC or an aliphatic polyurethane SCVC. Patients were
screened weekly by ultrasound for SCVC-related DVT. Potential risk factors were collected, including history-related,
trauma-related and SCVC-related characteristics.
Results: A total of 186 patients were included with a median Injury Severity Sore of 30 and a high rate of severe
brain injuries (21% of high intracranial pressure). Incidence of SCVC-related DVT was 37% (95% confidence interval:
26 to 40) in patients or 20/1,000 catheter-days. SCVC-related DVT occurred within 8 days in 65% of cases. There
was no significant difference in DVT rates between the aromatic polyurethane and aliphatic polyurethane SCVC
groups (38% vs. 36%). SCVC-related DVT independent risk factors were age >30 years, intracranial hypertension,
massive transfusion (>10 packed red blood cell units), SCVC tip position in the internal jugular or in the innominate
vein, and ipsilateral jugular catheter.
Conclusion: SCVC-related DVT concerned one-third of these severely traumatized patients and was mostly
clinically silent. Incidence did not depend on the type of polyurethane but was related to age >30 years,
intracranial hypertension or misplacement of the SCVC. Further studies are needed to assess the cost-effectiveness
of routine screening in these patients in whom thromboprophylaxis may be hazardous.
Keywords: central venous catheter, upper extremity deep vein thrombosis, risk factors, multiple trauma, intracranial
hypertension
Introduction
The incidence of central venous catheter (CVC)-related
deep venous thrombosis (DVT) varies considerably in the
ICU, depending on the population included and the
detection methods [1,2]. The rate of subclavian central
venous catheter (SCVC)-related DVT found by routine
Doppler ultrasound in the literature ranges from 4 to
67% with a mean incidence of 30%, of whom only 2%
were symptomatic [3]. Several thrombotic risk factors
have been identified and are related either to the patient’s
condition or to the catheter [4].
With regard to insertion sites, a femoral insertion is
known to increase the risk of infection or thrombosis.
The incidence of CVC-related DVT in the upper extre-
mities is estimated to be 2 to 6% when symptomatic and
11 to 19% when asymptomatic [5]. In their conclusion,
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the experts of the Cochrane review group stated that it is
probably reasonable to prefer subclavian access to
femoral access [6]. The CVC equipment may also be a
risk factor. The incidence of thrombosis is higher with a
CVC made of polyethylene than one made of polyur-
ethane [7]. Most CVC are now composed of polyur-
ethane. In our hospital, two brands are available and both
are made of polyurethane. One CVC is made of aromatic
polyurethane (Ar) and is the most commonly used. Our
Medical Devices Vigilance has collected reports about
thrombosis associated with its use. Another brand is
made of aliphatic polyurethane (Al). This Al CVC is mar-
keted as being more thermosensitive than Ar, so its
thrombogenic potential is theoretically lower.
Trauma patients have specific risk factors and the use of
anticoagulant is often problematic in the initial phase
because of the risk of bleeding. Studies in trauma patients
have found widely varying rates of overall DVT from 0.36
to 58% depending on the patients studied and the means
used to diagnose DVT [8-10]. However, most studies in the
specific setting of trauma patients are not limited to the
ICU.
The aim of this study was to identify SCVC-related DVT
risk factors in ICU trauma patients and to determine
whether the type of polyurethane used could be an inde-
pendent risk factor. The study was performed regardless




This prospective, single-center study took place in a 25-bed
surgical trauma ICU at Bordeaux University Hospital. This
level 1 trauma center, serving the southwest of France
(2.8 million inhabitants), takes care especially of severe
brain or spinal cord injuries. The institutional review board
at the University Hospital of Bordeaux approved the study
and waived the need for informed consent because the
study was observational and did not interfere in the treat-
ment of patients (IRB du CHU de Bordeaux; Chairman:
M. Leroy; Reference: JPL/JB/GD/1317/2008/RC).
We included adult patients (≥18 years), with trauma
(Injury Severity Sore (ISS) >8), needing at least one CVC
for an estimated length >5 days. Subclavian insertion was
the only access route considered in this study. We
excluded patients with known DVT risk factors, such as
thromboembolic history, thrombophilia, malignancy,
patients with anticoagulant treatment at the time of their
injury, and patients needing immediate therapeutic antic-
oagulation for their injury.
Catheters
Two kinds of catheter are available in our hospital: an
Ar SCVC (Blue FlexTip® catheter; Arrow International,
Reading, PA, 19605 USA) or an Al SCVC (Seldiflex®;
Prodimed-Plastimed, F95130 LePlessis Bouchard,
France), To test the kind of CVC as an independent risk
factor, the type of available CVC (Ar or Al) was estab-
lished on a monthly randomized basis.
Deep venous thrombosis screening
DVT screening of the upper extremities was performed by
venous duplex ultrasound scanning as a preliminary study
to set up a new systematic protocol of DVT screening in
our ICU. Examinations took place first between 5 and
7 days after trauma occurrence and then weekly, with the
last one at the time of SCVC ablation or a few days after.
The ultrasound examinations were performed by two US-
licensed anesthesiologists (LP, VC) using an Acuson
CV70, Siemens Medical Solution, Mountain View, CA
94043 USA with a high-frequency transducer dedicated to
vascular imaging (5 to 10 MHz). A DVT was defined as
partial if the vein was still partly compressible, or as com-
plete when no venous flow could be detected. Thrombosis
was considered SCVC related when a partial or complete
thrombus was found in the subclavian or axillary or hum-
eral veins with the SCVC in this territory. The examina-
tion concerned the superior vena caval territory ipsilateral
and contralateral to the SCVC and the lower limbs
(femoral vein up to popliteal vein).
Data collection
The following data were collected: age, sex, date of admis-
sion, comorbidities, injury mechanism, and Simplified
Acute Physiologic Score II. Injuries were recorded and
their severity coded according to the Abbreviated Injury
Score (AIS) maximum for each body region and to the
ISS. Other data were collected concerning difficulties at
the time of insertion, parenteral nutrition, medications
infused through the catheter, transfusion, microbiologi-
cally documented concomitant infections (bacteremia or
pneumonia), length of catheter maintenance, reason for
removal, and results of catheter culture.
Coagulation screening tests performed at the time of each
examination included standard tests (prothrombin time,
activated partial thromboplastin time, platelet count) and
specific assays for D-dimer, fibrinogen, factor II, factor V,
and factor X.
A clinical examination was performed by a senior
medical doctor before the first ultrasound examination
in order to determine whether a DVT was likely or very
likely based upon signs such as warmth, edema and col-
lateral circulation.
Statistical analysis
The SCVC type was considered the main potential risk
factor. A preliminary study showed that the Ar-SCVC-
related DVT incidence was 27%. A sample size of 112
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patients in each group would make it possible to detect a
15% difference in the percentage of DVT incidence (con-
sidered clinically significant) with a power of 80%.
Quantitative data are presented as mean ± standard
deviation or as median with 25 to 75th quartiles (inter-
quartile range (IQR)) according to their distribution. Com-
parisons between patients were performed using the chi-
square test or Fisher’s exact test as appropriate, and the
Student t test or the Mann-Whitney test for quantitative
variables according to their distribution. The value of the
clinical examination to determine a SCVC-related DVT
was estimated by calculating positive and negative predic-
tive values. Rates were calculated in patients and also
reported as DVTs/1,000 catheter-days. Univariate and
multivariate logistic regression analysis were performed to
identify independent risk factors for development of
SCVC-related DVT. All variables associated with a SCVC-
related DVT risk with P <0.20 in the univariate analysis
were investigated using multivariate analysis, with SCVC-
related DVT as the dependent factor and other factors as
the independent factors. Statistical significance was set at
P <0.05 for all analysis.
Results
Four hundred and eighty-six patients were screened dur-
ing 21 months. Two hundred and ninety-five patients
were not included for various reasons: cancer history,
associated anticoagulation, CVC set up before transfer to
our hospital, CVC in a femoral vein, estimated required
duration of CVC <5 days, or logistic reasons (impossible
to follow more than 10 patients at the same time on a
weekly basis). Five patients were secondarily excluded
(early death or early CVC removal). Finally, 186 patients
were included in the analysis (84 in the Ar group and 102
in the Al group). Most were male (80%). Known DVT risk
factors related to the patients’ medical history were
uncommon (Table 1). The median ISS was 30, meaning a
majority of polytraumatized patients. The rate of severe
brain-injured patients was high. One-half of the included
patients had an initial Glasgow Coma Score <8, 37% of
patients had a maximum head AIS equal to 5, and 21%
developed severe intracranial hypertension (ICHT), one-
half of them needing barbiturates to control their ICHT.
The median length of stay was 20 days (IQR: 13 to 31)
and the median length of catheterization was 13 days
(IQR: 8 to 19). The CVC were mostly three lumina (16G/
18G/18G), with a diameter of 7 Fr and a length of either
15 or 20 cm, depending on the placement side, respec-
tively right or left.
Subclavian central venous catheter-related
DVT incidence
Sixty-two patients developed a DVT diagnosed while the
SCVC was in place (incidence 33%) and seven more were
found 1 to 5 days after ablation of the SCVC (overall inci-
dence 37%; 95% confidence interval: 26 to 40) (Table 2).
The incidence was 64% in patients with ICHT and 30% in
other trauma patients. In medullar-injured patients (AIS 4
Table 1 Demographic and medical characteristics of
included patients and between-group comparison








Age (years) 38 ± 16 39 ± 16 37 ± 16
Weight (kg) 79 ± 16 78 ± 15 79 ± 16
Sex (male) 150 (81%) 67 (80%) 83 (81%)
History
Hypertension 13 (6%) 7 (9%) 6 (6%)
Diabetes 6 (3%) 2 (2%) 4 (4%)
Smokers 71 (43%) 34 (44%) 37 (42%)
Scores
SAPS II 34 (24 to 43) 32 (24 to 43) 33 (24 to 41)
ISS 29 (25 to 38) 29 (25 to 38) 30 (25 to 38)
Head AIS ≥3 131 (70%) 61 (73%) 70 (68%)
Chest AIS ≥3 91 (49%) 37 (44%) 54 (53%)
Abdominal AIS ≥3 31 (17%) 12 (14%) 19 (19)%
Pelvic AIS ≥3 47 (25%) 20 (24%) 27 (26%)
Spine AIS ≥3 38 (20%) 17 (20%) 21 (21%)
Injuries and treatments
Upper extremity injury 53 (28%) 24 (29%) 29 (28%)
GCS <8 84 (40%) 34 (49%) 40 (48%)
CHT 39 (21%) 18 (21%) 21 (21%)
Barbiturates 23 (12%) 9 11%) 14 (14%)
Transfusion 65 (35%) 23 (27%) 42 (41%)
Results presented as mean ± standard deviation, as median (25th to 75th
quartiles) or as number of patients (%). AIS, Abbreviated Injury Scale; Al,
aliphatic polyurethane; Ar, aromatic polyurethane; GSC, Glasgow Coma Score;
ICHT, intracranial hypertension; ISS, Injury Severity Score; SAPS II, Simplified
Acute Physiologic Score II on ICU admission; SCVC, subclavian central venous
catheter. No statistically significant difference between the two groups.
Table 2 Demographic and medical characteristics of
included patients and between-group comparison







DVT on SCVC in place 62 (33%) 29 (35%) 33 (32%)
DVT after SCVC removal 7 (4%) 3 (4%) 4 (4%)
Total SCVC-related DVT 69 (37%) 32 (38%) 37 (36%)
Diagnosed at first examination 44 (64%) 18 (56%) 26 (70%)
Extent
1 vein 37 (20%) 15 (18%) 22 (22%)
2 veins 17 (9%) 8 (9%) 9 (9%)
>2 veins 15 (8%) 9 (11%) 6 (6%)
Occlusive character 25 (13%) 15 (18%) 11 (11%)
Results presented as number of patients (%). Al, aliphatic polyurethane; Ar,
aromatic polyurethane; DVT, deep vein thrombosis; SCVC, subclavian central
venous catheter. No statistically significant difference between the two groups.
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or 5 in the spine region), the incidence was 27%. One-
third of these DVTs were occlusive. One-half of the CVC-
related DVTs involved only one vein, mostly the jugular
vein, which was involved in 61% of DVT, and one-half
involved at least two veins. Most were diagnosed early at
the first ultrasound examination (65%): 44 were found at
the end of the first week (24% of screened SCVCs), 16 at
the end of the second week (16% of the 105 free SCVCs
screened) and nine (23% on the 39 free SCVCs screened)
at the end of the third week. These thromboses were
mostly subclinical. The positive predictive value of the clin-
ical examination was 29% and the negative predictive value
was 74%. When considering only complete thrombosis
(with an occluded vein), only two out of 10 were consid-
ered ‘very likely thrombosed’.
Associated thrombosis
Ten upper-limb DVTs were found in patients without an
ipsilateral SCVC: in five cases the two sides were thrombo-
tic, two patients had a jugular catheter on the side of the
thrombosis and three occurred only on the opposite side
that was free of any catheter.
There were 22 cases of above-knee DVT in the 186
patients (12%) and the femoral vein was involved in 20 out
of 22. They also occurred early: 45% were found at the
first ultrasound examination. Thirteen occurred in patients
with SCVC-related DVT (19% in patients with a SCVC-
related DVT and 8% among those who were free, P <
0.05). They were found at the same examination in six
cases, before SCVC-related DVT in two cases and after
SCVC-related DVT in five cases. The overall incidence of
thrombosis in this sample of very severe trauma patients
was thus 44%.
Type of catheter as risk factor
The Ar group and the Al group were comparable concern-
ing demographic and trauma characteristics (Table 1). The
overall rate of SCVC-related DVT was 38% in the Ar
group and 36% in the Al group (P = 0.93) (Table 2).
Other patient-related risk factors
Mean age was not statistically different between the two
groups (Table 3). However, the incidence of DVT was
lower in patients ≤30 years old (25.7%) than in those
between 31 and 50 years old (47%) or >50 years old (40%)
(P < 0.05). SCVC-related DVT risk factors in relation to
trauma characteristics are shown in Table 4. ICHT and
treatment with barbiturates were significantly associated
with a higher risk of SCVC-related DVT. Other head inju-
ries, chest or abdominal or spinal cord or limb injuries did
not appear associated with an increased risk of SCVC-
related DVT. The rate did not depend on the ISS (Table
4) or on the number of severely injured regions (AIS ≥3)
of the body (36% with one region, 35% with two regions,
42% with three or four regions). Neither patients needing
a cervical collar nor those suffering from a clavicle or
humerus fracture developed more SCVC-related DVTs,
although a worsened venous return might be expected in
such settings. Eight patients needed more than 10 packed
red blood cells and six out of eight developed a thrombosis
on their CVC. There was a tendency for CVC thrombosis
risk in patients requiring treatment with vasopressor
amines. A jugular venous catheter was inserted on the
same side as the SCVC in 19 patients, including 15 with
SCVC-related DVT (79%).
At the first examination, no difference could be found in
coagulation standard tests between patients with or with-
out a CVC-related DVT. D-dimers were very high in both
groups (4,696 ± 2,730 ng/ml in DVT-negative patients vs.
5,034 ± 2,727 ng/ml in DVT-positive patients). Finally, a
more prolonged inflammatory status seemed to be asso-
ciated with a higher risk of SCVC-related DVT. At the
first examination, the mean C-reactive protein was 160 ±
89 mg/l in patients whose examination showed a throm-
bosis and 151 ± 79 mg/l in the other patients (P = NS). In
patients who were free of DVT at the first examination,
the mean C-reactive protein at the end of the second week
was 153 ± 87 mg/l in patients who had a thrombosis at
this second examination versus 82 ± 61 mg/l in patients
still unaffected (P <0.005). We found no relationship
between the C-reactive protein level measured weekly dur-
ing the first 3 weeks and the occurrence of pneumonia or
septicemia during the duration of catheterization. Nor did
we find any relation between the highest C-reactive pro-
tein level during the study in each patient and the occur-
rence of any infectious episode during the same period.
Introduction of thromboprophylaxis (subcutaneous low
molecular weight heparin (LMWH)) or curative heparin
(mainly LMWH) was decided on a case-by-case basis.
Thromboprophylaxis was prescribed in 117 patients dur-
ing the duration of the study with a median delay of 13
days after the trauma. This delay was different between
brain-injured and other patients: 15 ± 6 days when maxi-
mum head AIS >2 (thus including significant intracerebral
injuries) versus 11 ± 6 days in other patients. Five patients
developed SCVC-related DVT while anticoagulant therapy
or prophylaxis was ongoing: for 5 days in one patient and
for >10 days in four others (including one who was treated
by heparin infusion for a femoral thrombosis). The rate of
SCVC-related DVT was 41% in patients without any pro-
phylaxis during their follow-up versus 7.5% in patients
with heparin prophylaxis (P <0.001). SCVC-related DVT
occurring while the patients were receiving LMWH
occurred later (median 16 days; IQR: 9 to 21) than in
SCVC-related DVT without prophylaxis (median 7 days;
IQR: 6 to 11) days). In the event of SCVC-related DVT,
anticoagulant treatment was given immediately in 17 cases
and later in 25 others.
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Risk factors related to subclavian central venous catheter
Forty-three patients received two SCVCs and three
patients received three SCVCs. Two patients developed
two SCVC-related DVTs during their stay. Thus 71
SCVC-related DVTs occurred among the 235 SCVCs for
a total of 3,493 days of catheterization (20 SCVC-related
DVTs/1,000 days).
The rate of DVT did not depend on the number of
lumens (Table 5). A SCVC tip misplaced in the internal
jugular or innominate vein was significantly associated
Table 4 Trauma characteristics in patients with and without subclavian venous central catheter-related deep venous
thrombosis
Characteristic SCVC-related DVT (n =69) Not SCVC-related DVT (n =117)
Scores
SAPS II 36 (26-46) 32 (23-39)
ISS 31 (25-38) 29 (25-36)
AIS ≥ 3
Head 52 (75%) 79 (67%)
Chest 38 (55%) 53 (45%)
Abdominal 10 (14%) 21 (18%)
Pelvic/lower extremities 14 (20%) 33 (28%)
Spine 14 (20%) 24 (20%)
Injuries and clinical complications
Ipsilateral humerus fracture 2 (3%) 8 (7%)
Ipsilateral clavicle fracture 1 (1%) 5 (4%)
Surgery on first day 22 (32%) 50 (43%)
GCS <8 37 (54%) 46 (39%)
Intracranial hypertension 29 (42%) 15 (13%)**
Acute respiratory distress syndrome 9 (13%) 14 (12%)
Treatments
Barbiturates 14 (20%) 9 (8%)*
Jugular catheter on same side as SCVC 15 (22%) 4 (3%)***
Transfusion 23 (33%) 42 (36%)
Packed red blood cells n >10 6 (9%) 2 (2%)*
Vasopressor amines 56 (81%) 80 (68%)
Cervical collar 13 (19%) 27 (23%)
Surgical intervention in first 24 hours 23 (33%) 56 (48%)
Results presented as median (25th to 75th quartiles) or as number of patients (%). AIS, Abbreviated Injury Scale; DVT, deep vein thrombosis; GCS, Glasgow coma
score; ISS, Injury Severity Score; SAPS, Simplified Acute Physiologic Score; SCVC, subclavian central venous catheter. *P <0.05; **P <0.01; ***P <0.001.
Table 3 Characteristics of patients with and without subclavian venous central catheter-related deep venous
thrombosis
Characteristic SCVC-related DVT (n = 69) Not SCVC-related DVT (n = 117)
Demographic characteristics
Sex (male) 54 (78%) 96 (82%)
Age (years) 40 ± 14 37 ± 17
Weight (kg) 78 ± 14 80 ± 17
Height (cm) 172 ± 14 174 ± 11
Clinical history
Obesitya 12 (17%) 24 (20%)
Hypertension 6 (9%) 7 (6%)
Diabetes 1 (1%) 5 (4%)
Smokers 26 (40%) 45 (44%)
Sepsis during catheterization length
Bacteraemia 1 (1%) 8 (7%)
Pneumonia 40 (58%) 72 (62%)
Results presented as mean ± standard deviation or as number of patients (%). Percentages are calculated from the number of patients for which data are
available. DVT, deep vein thrombosis; SCVC, subclavian central venous catheter. No statistically significant difference between the two groups. aObesity defined
by body mass index >30.
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with an increased risk of SCVC-related DVT. The SCVC
tip was misplaced and not removed in 20 cases (9%):
SCVC thrombosis occurred in 65% of these cases within 6
days instead of 27% in patients were SCVC tip was cor-
rectly placed (P <0.0001). Administration of parenteral
nutrition was associated with a higher incidence of SCVC
thrombosis while the rate of SCVC-related DVT was
lower in patients who received propofol via the SCVC.
The occurrence of SCVC-related DVT was not different in
patients with a septic episode during catheterization: 28%
of DVTs if pneumonia during catheterization versus 33%
if not; 11% if bacteremia versus 31% if not.
Upon removal, the catheter tips were systematically col-
lected for bacteriological analysis. This analysis was available
in 225 cases: catheter colonization (≥103 colony-forming
units/ml) was found in 2.9% of thrombotic SCVCs versus
2.5% without (P = NS). Colonization did not depend on the
length of catheterization (15 ± 11days in colonized SCVCs
vs. 14 ± 9 days in others). Among the 71 SCVC-related
DVTs, 18% were found after SCVC removal; 38% SCVCs
still in place were removed within 0 to 3 days after discovery
of SCVC-related DVT, while 48% were left in place longer.
Multivariate analysis
In the multivariate analysis, age was analyzed in two
groups: ≤30 years old and >30 years old. The independent
factors associated with SCVC-related DVT were age >30
years, ICHT, transfusion >10 packed red blood cell units,
misplaced SCVC tip position and LMWH before DVT
(Table 6).
Short-term outcome of subclavian central venous
catheter-related DVT
Forty-nine SCVC-related DVTs were revised after the
date of thrombosis. SCVC-related DVTs disappeared in
23 cases (47%). Healing was observed in 50% of cases
where the SCVC was left in place and 44% where it was
removed (P = NS). Healing had occurred at the last
examination in 12 out of 27 (44%) patients with LWMH
and in 11 out of 22 (50%) patients without this treatment
(P = NS). Two patients presented a pulmonary embolism
(PE) confirmed by radiological imagery. One was found
to have occlusive thrombi both around the SCVC and in
the leg. This patient was treated with heparin and the
thrombi disappeared. He had a PE 20 days later. In
another patient no thrombus was found at the time of
the last ultrasound examination when the CVC was
removed. A PE was then diagnosed 4 days later and
another ultrasound examination showed an occlusive
thrombus at the site of the former SCVC. A PE was sus-
pected in three more patients who presented a brief
hypoxic episode at the time of CVC removal. Lastly, a
patient suddenly died 1 month after having developed a
CVC thrombosis, despite receiving curative anticoagulant
treatment. This could have been due to a PE, although
no radiological examination was available to confirm this
hypothesis. One patient was discharged with occlusive
SCVC-related DVT under anticoagulant therapy. She was
hospitalized again 1 year later and the DVT was still
occlusive.
Discussion
The incidence of subclavian SCVC-related DVT con-
cerned one-third of these patients. The hypothesis that Ar
might lead to more thrombosis than Al is not confirmed.
Only 186 patients were included in the study instead of
the 224 originally planned. The clinical impress during the
study was equivalence between the two products. An inde-
pendent statistical team was consulted and found that the
difference in SCVC-related DVT incidence between the
Table 5 Subclavian venous central catheter characteristics in relation to deep venous thrombosis
Characteristic Total
(n = 235)
SCVC-related DVT (n =71) Not SCVC-related DVT (n =164)
Placement procedure
Placement in emergency room 171 (73%) 55 (77%) 116 (71%)
Left-sided 158 (67%) 52 (73%) 105 (64%)
SCVC characteristics
Number of lumina
2 11 (5%) 3 (4%) 8 (5%)
3 199 (85%) 60 (86%) 137 (84%)
>3 25 (11%) 7 (10%) 18 (11%)
Misplaced SCVC tip 20 (9%) 13 (19%) 7 (4%)**
Colonizationa 6 (2.5%) 2 (2.9%) 4 (2.5%)
Treatment delivered via SCVC
Propofol 142 (61%) 35 (50%) 107 (65%)*
Parenteral nutrition 90 (38%) 34 (49%) 56 (34%)*
Results presented as number of SCVCs (%). Percentages are calculated from the number of SCVCs for which data are available. DVT, deep vein thrombosis; SCVC,
subclavian central venous catheter. aSCVC colonization (≥103 colony-forming units/ml) - data available on 225 SCVCs. *P <0.05; **P <0.01.
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Ar group and the Al group was as low as 2%. The number
needed to have a good probability to demonstrate that this
difference was significant should have been too high.
Because such a small difference was not expected to have
any impact on clinical practice, we decided to stop the
study.
Other SCVC characteristics, such as multiple lumina and
left-side SCVC placement, also did not appear associated
with a higher risk of SCVC-related DVT in trauma patients,
although they have been reported in other studies [11-13].
Parenteral nutrition was associated with a higher rate of
SCVC-related DVT. Propofol seemed to have an opposite
effect. Parenteral nutrition may have some impact on coa-
gulation parameters [14]. We did not find any report of a
protective effect of propofol. In our study these relations
might be due to a statistical bias because patients who
received parenteral nutrition had a higher frequency of
ICHT while those sedated with propofol were the least
severely injured. These two factors did not remain signifi-
cant in the multivariate analysis. A CVC in the internal
jugular vein ipsilateral to the SCVC was an independent
risk factor for thrombosis. These jugular catheters were
mostly set up to monitor cerebral blood saturation, which
required retrograde cannulation into the jugular bulb. The
analysis confirmed the high risk of not centrally positioning
the tip of the subclavian CVC [8,15]. The CVC placement
conditions in our emergency room may also explain the
high rate of SCVC-related DVT [16].
Our results also confirm the recent report that massive
transfusion (defined as >10 packed red blood cells. seems
to favor SCVC-related DVT, although no threshold has
been identified to date [17]. In this study there was no evi-
dence of a relationship between infection during catheteri-
zation time and SCVC-related DVT. The infection rate
was high but consisted mostly of pneumonia. Bacteremia
was rare and occurred only once in association with
SCVC-related DVT and that very low incidence may have
a bearing on our results. Raad and colleagues found a rela-
tionship between mural thrombosis found at postmortem
examination and catheter-related septicemia, but catheter-
ization was of long duration before the examination (mean
63 days) and all patients had cancer [18]. Timsit and col-
leagues found that the relative risk of catheter-related sep-
ticemia was threefold higher when a thrombosis was
present in critically ill patients [19]. The duration of cathe-
terization was comparable with our study while their rate
of colonization was >20%. However, 35% of their patients
were admitted with an ongoing infectious disease [19].
Our DVT occurred very early and seemed to be associated
more with inflammation due to trauma than to intercur-
rent infection.
The patients included in our study had both a SCVC
and a major trauma. The following risk factors were
identified in the various studies on trauma patients: older
age (>40 or >60 years old), transfusion, surgery, spinal
cord injury, pelvic fracture, head injury, and mobility
score. Our patients were particularly vulnerable to DVT.
First, the patients were in an ICU for severe polytrauma
and during the first week they were all immobilized by
sedation to allow iterative surgical treatment and
mechanical ventilation. Secondly, 70% of these patients
had severe brain injury. A brain injury was demonstrated
to increase threefold to fourfold the risk of developing a
clinically diagnosed DVT, whatever the pharmacological
prophylaxis, in two large cohorts of patients admitted to
trauma centers [8,20]. In a study on 677 moderately and
severely brain-injured patients monitored by duplex
scans, a femoral DVT was present in 24% and an upper
extremity DVT in 16%. The prevalence of SCVC was not
detailed and the authors did not study incidence by
severity level of the brain injury [21]. In our patients,
brain injury without ICHT was not associated with
a higher rate of SCVC-related DVT, whereas ICHT
increased the risk fivefold and this association had not
Table 6 Risk factor predictors of subclavian venous central catheter-related deep venous thrombosis
Predictor Univariate analysis Multivariate analysis
Age (per year of age) 1.01 (0.99 to 1.03)†
Age >30 years 2.3 (1.2 to 4.4)** 3.6 (1.6 to 8.0)**
Injuries and treatments
Intracranial hypertension 4.9 (2.4 to 10.2)*** 6.1 (2.6 to 14.4)***
Packed red blood cells n >10 2.7 (0.7 to 9.9)† 8.3 (1.7 to 40.0)*
Vasopressor amines 2.0 (0.9 to 4.1)†
Parenteral nutrition 1.7 (0.8 to 3.2)†
Initial surgical intervention 0.5 (0.3 to 1.0)†
LMWH 0.11 (0.04 to 0.3)*** 0.1 (0.02 to 0.2)***
SCVC characteristics
Misplaced tip position 4.7 (1.7 to 12.9)*** 10.2 (2.8 to 37.0)*
Ipsilateral jugular SCVC 6.0 (2.6 to 16.2)***
Results presented as odds ratio (95% confidence interval). In patients with subclavian central venous catheter (SCVC)-related deep venous thrombosis (DVT), only
low molecular weight heparin (LMWH) prescribed before DVT was considered. †P <0.20; *P <0.05; **P <0.01; ***P <0.001.
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yet been demonstrated. This increase in SCVC-related
DVT incidence in case of ICHT may be related to coagu-
lation disorders that occur after head injuries [22,23].
Coagulation activation from cerebral blood has been
demonstrated very early after a head trauma [24], prob-
ably induced by tissue factor release from the injured
brain. Sustained coagulopathy is more frequent in
patients with tomographic signs of intracranial hyperten-
sion (compressed cisterns or midline shift) [25]. In other
studies, fibrin degradation products levels were demon-
strated to be related to the severity of brain damage [22].
SCVC-related DVT is a particularly underestimated
complication. Clinical signs of SCVC-related thrombosis
are neither sensitive nor specific [2,5,26,27]. In polytrau-
matized patients the diagnosis of thrombosis is especially
difficult in view of the edema related to their orthopedic
injuries. In a study of 208 patients with femoral or subcla-
vian CVC screened by ultrasound in an ICU, 33%
of the patients developed CVC-related DVT but none
were symptomatic [19]. This was the case in our study.
The clinical screening therefore appears ineffective. On
the other hand, ultrasound screening is a noninvasive effi-
cient bedside tool, as already demonstrated in orthopedic
surgery [28,29]. The clinical importance of asymptomatic
DVT remains to be demonstrated. PE occurred in 0 to
17% of cases after an upper-arm DVT in two studies
[30,31]. In both studies, however, 10 to 20% of patients
had a neoplasm and the responsibility of the catheter
is thus difficult to determine. In the RIETE registry of
patients with symptomatic upper-extremity DVT or PE,
recurrent PE occurred in 3.8% of patients with cancer and
1.6% in those without [32]. In all these cases, however, the
DVT was symptomatic.
The second complication may be a post-thrombotic syn-
drome. Prandoni and colleagues found a 17% cumulative
incidence of post-thrombotic syndrome in patients with
vein catheter at 1 year but their study concerned only
symptomatic upper-arm DVT [33]. Few studies have
reported data on the incidence and the range of estimates
is wide, reflecting the heterogeneity of patients studied
[34]. Whether SCVC-related DVT patients have the same
risk of developing long-term post-thrombotic syndrome as
other DVT patients is not clear. All of these complications
have been studied in symptomatic patients. The complica-
tions that may be linked to asymptomatic SCVC-related
DVT remain to be confirmed. In Malinoski and colleagues’
study, DVT was diagnosed by systematic ultrasound
examination and the rate of PE after catheter-associated
upper extremity DVT was 1.3% despite generalized throm-
boprophylaxis [35]. In our study, a diagnosis of PE was
confirmed twice. One PE occurred 20 days later than the
occurrence of the SCVC-related DVT and was associated
with a lower-limb DVT; both DVTs had disappeared
when the patient left the ICU. The involvement of the
SCVC-related DVT was uncertain. In the second case, the
patient was free of DVT at the end of the ICU stay and PE
occurred later. The DVT was found near the site of SCVC
placement. Three other patients experienced brief episodes
of hypoxia when the SCVC was removed. Although these
events may seem anecdotal, we think that clinicians should
keep in mind the potential harmfulness of SCVC-related
DVTs.
High-risk patients should benefit from improved preven-
tive measures. Clinicians are hesitant to use chemoprophy-
laxis because of the risk of intracranial hemorrhage.
LMWH has proved effective as pharmacologic thrombo-
prophylaxis in ICU trauma patients [2,9,17]. However, a
recent study demonstrated that pharmacologic thrombo-
prophylaxis use is associated with a 13-fold increased odds
of further hemorrhage progression in patients whose fol-
low-up computed tomography within 1 day of admission
showed an intracranial hemorrhage increase [36]. Patients
at high risk of SCVC-related DVT but presenting a high
risk of bleeding could thus not benefit from the antici-
pated pharmacologic thromboprophylaxis. The benefit of
therapeutic anticoagulation was not demonstrated in our
patients who underwent examinations after SCVC-related
DVT had been diagnosed. At the time of the study, we
were very careful about prescribing anticoagulants. When
prescribed, the decision was made on the basis of the
extent of the thrombosis, and the severity of intracranial,
hepatic or pulmonary hemorrhagic contusions. The doses
were possibly underestimated in patients with a severe
inflammatory condition. However, in the study by Mali-
noski and colleagues on surgical and trauma patients,
anticoagulation was not associated with a higher rate of
resolution [35]. Our decision to remove the SCVC was
also taken on a case-by-case basis according to the extent
of the thrombosis and according to the technical possibi-
lity of using another infusion mode. One of our main con-
siderations was not to send a significant clot into the
blood flow.
These findings have led us to implement preventive
measures to decrease SCVC thrombosis. An educational
film about good practices in CVC insertion has been
made, which is now available for both junior and senior
practitioners. Second, any SCVC whose tip is misplaced
in the internal jugular vein or in the innominate vein is
removed. The use of ultrasound for SCVC placement
decreases the number of punctures and the failure rate,
and is now encouraged [37,38]. Third, Duplex ultrasound
examinations are now performed by most physicians in
our service. They are systematic in all patients at the end
of the first week since our study demonstrated that 60%
of DVTs occurred within this delay, and then before
removing the SCVC. Last, the time of chemoprophylaxis
is discussed earlier, on a case-by-case basis, taking into
account the risk of intracranial bleeding propagation.
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At the beginning of the study, thromboprophylaxis was
prescribed late. Nowadays, we assess the risk-benefit
ratio of beginning prophylaxis much earlier.
Conclusion
This study demonstrates that SCVC-related DVT is a fre-
quent and early complication in severe polytraumatized
patients, and its incidence does not depend on the type of
polyurethane. SCVC-related DVT concerns one-third of
patients and occurs early within the first week. The main
risk factors were intracranial hypertension, a misplaced
SCVC, or a massive transfusion. SCVC-related DVT is
often underdiagnosed because it is mostly asymptomatic.
Further large prospective studies are required to confirm
our findings, to identify other risk factors, to study long-
term morbidity linked to these SCVC-related DVTs and
to evaluate the cost-effectiveness of systematic screening
by venous ultrasound in these patients in whom pharma-
cologic thromboprophylaxis may be hazardous.
Key messages
• The incidence of SCVC-related DVT does not depend
on the kind of polyurethane.
• The main risk factors are intracranial hypertension
and misplaced SCVC.
• One-half of CVC-related DVTs were found at the
end of the first week after trauma.
• Routine coagulation tests do not help to diagnose
these DVTs.
• The long-term consequences of these asymptomatic
SCVC-related DVTs would be investigated to determine
their clinical impact.
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